Medical News / ERS 2020: Monotherapy LAMA is Over-Used, Linked to Asthma Exacerbation Risk

Long-acting muscarinic antagonists (LAMA) are frequently prescribed out of step with guidance for treating patients with asthma, according to a new study. In new data presented virtually during the European Respiratory Society (ERS) 2020 Congress this week, a team of investigators from the Netherlands and Belgium showed monotherapy LAMA is prevalent among nearly 40% of observed users with asthma—despite its indication being for add-on use. Source: MDMag To view the third party content, kindly click on the link below or read more. You will then leave this site and enter a third party site.

read more

Patients with severe asthma have an increased susceptibility to respiratory tract infections with rhinovirus (HRV) causing ... read more
Personalized medicine might be a realistic target in many specialties in the next decade, including pulmonology. Recently, ... read more
When the coronavirus disease 2019 (COVID-19) pandemic began it was conventional wisdom that asthma patients might ... read more
Researchers have previously confirmed impulse oscillometry (IOS) can be used to detect asthma control, but the ... read more